These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of oral contraceptive containing a new progestin (ORG 2969) on plasma renin activity, growth hormone and immunoreactive insulin.
    Author: Liukko P, Erkkola R, Lammintausta R.
    Journal: Ann Chir Gynaecol; 1979; 68(5-6):155-9. PubMed ID: 161858.
    Abstract:
    Plasma renin activity (PRA), Growth hormone (GH) and immunoreactive insulin (IRI) were studied in seven healthy subjects during the ovulatory menstrual cycle and during the first and third cycles of oral contraception with 0.05 mg of ethinylestradiol and 0.100 mg or 0.125 mg of a new progestogen, 17 alpha-ethinyl-18-methylene-4-estren-17 beta-ol. The PRA level in the second half of the control cycle was significantly higher than in the beginning of the cycle. At the end of the treated cycles it was significantly higher than at the end of the control cycle. Neither GH nor IRI showed significant changes during the control cycle. GH was significantly higher at the end of the first and third treated cycles than at the end of the control cycle. IRI was significantly higher both in the beginning and at the end of the first treated cycle than the corresponding IRI levels in the control cycle. IRI at the end of the third treatment cycle was not significantly different from corresponding means at the end of the control cycle or the first treated cycle. A new oral contraceptive (Org 2969) formulated of .05 mg of ethinyl estradiol and .1 mg or .125 mg of a new progestagen, 17 alpha-ethinyl-18-methyl-11-methyl-ene-4-estren-17 beta-ol, was studied to determine its effects in human volunteers on plasma renin activity (PRA), growth hormone (GH), and immunoreactive insulin (IRI). 7 healthy subjects were studied during an ovulatory menstrual cycle and during the 1st and 3rd cycles of oral contraception. 1 of 7 subjects showed ovulation after the 1st cycle of contraceptives; the remainder were anovulatory, and all subjects were anovulatory by the 3rd cycle of contraception. PRA on the 22nd day of the control cycle was significantly (P .01) higher than the mean PRA on days 2-5 of control. Mean PRA at the beginning of the 1st treatment cycle was not significantly higher than control cycles. By day 22 of treatment, however, it was significantly (P .001) higher than day 22 of control cycle. A significant PRA Increase after the 1st treatment cycle (P .05) was noted along with a continued significance in the 3rd cycle (P .05). At the end of the treatment cycle, GH was significantly higher (P .05) than at the end of the control cycle. The rise of GH over the 1st treatment cycle compared with control cycle was insignificant, but after the 3rd treatment cycle, GH was significantly higher than the control cycle values (P .05). There were no differences in GH throughout the control cycle. IRI did not differ within the control cycle. By the 2nd-4th day of the 1st treatment cycle, mean IRI was significantly higher than comparable control cycle values (P .01). The rise in IRI during treatment was also significant (P .05). No correlations were found among the individual GH and IRI values, and no significances for same sampling periods were found. Levels of the 3 parameters were unaffected by dosage of the new progestin.
    [Abstract] [Full Text] [Related] [New Search]